<DOC>
	<DOCNO>NCT00288002</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , epirubicin , cyclophosphamide , docetaxel , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Monoclonal antibody , trastuzumab , block tumor growth different way . Some find tumor cell kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Giving combination chemotherapy together monoclonal antibody surgery may make tumor small reduce amount normal tissue need remove . Giving monoclonal antibody surgery may kill tumor cell remain surgery . It yet know whether combination chemotherapy effective without capecitabine and/or trastuzumab treat breast cancer . PURPOSE : This randomized phase III trial study epirubicin , cyclophosphamide , docetaxel compare well work without capecitabine and/or trastuzumab surgery treat woman stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Capecitabine and/or Trastuzumab Before Surgery Treating Women With Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare pathologic complete response rate woman stage I-III primary breast cancer treat neoadjuvant epirubicin hydrochloride , cyclophosphamide , docetaxel versus without capecitabine follow surgery . - Compare pathologic complete response rate woman HER-2/neu-positive tumor receive trastuzumab ( Herceptin® ) simultaneously neoadjuvant epirubicin hydrochloride , cyclophosphamide , docetaxel woman HER-2/neu-negative tumor receive neoadjuvant chemotherapy . Secondary - Determine toxicity regimens patient . - Determine disease-free ( loco-regional distant ) survival overall survival patient treat regimen . - Determine disease-free ( loco-regional distant ) survival overall survival patient treat without trastuzumab . - Determine breast conservation rate patient treat regimen . - Determine frequency use sentinel node biopsy select patient neoadjuvant chemotherapy . - Compare frequency sentinel node biopsy surgery neoadjuvant chemotherapy arm . - Determine pathologic complete response rate regimen subgroup patient locally advanced ( T4a-d , N0-3 , M0 ) breast cancer . - Determine response rate ( complete response , partial response , change ) surgery ( image method histopathological exam ) patient subgroup accord response four treatment epirubicin hydrochloride cyclophosphamide . - Determine intention use neoadjuvant chemotherapy , term freedom disease , avoid mastectomy , improve breast conservation , gain information efficacy . OUTLINE : This randomize , control , open-label , multicenter study . Patients stratify accord participate site , clinical response 4 course epirubicin hydrochloride cyclophosphamide ( complete response v partial response v change ) , HER-2/neu-status ( negative v 3+ immunohistochemistry [ IHC ] positive fluorescence situ hybridization [ FISH ] ) , estrogen receptor ( ER ) /progesterone receptor ( PR ) status ( ER PR positive v ER PR negative ) , extent disease ( T4 N3 v T1-3 N0-2 ) . All patient receive epirubicin hydrochloride IV 30-60 minute cyclophosphamide IV 60 minute day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients randomize 1 3 treatment arm . - Arm I : Patients receive docetaxel IV 60 minute day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Arm II : Patients receive docetaxel arm I . Patients also receive oral capecitabine twice daily day 1-14 . Treatment docetaxel capecitabine repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Arm III : Patients receive docetaxel arm I . Patients receive oral capecitabine twice daily day 1-14 . Treatment capecitabine repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients HER-2/neu-positive tumor also receive trastuzumab ( Herceptin® ) IV 90 minute day 1 course chemotherapy ( treatment epirubicin hydrochloride cyclophosphamide AND randomize treatment ) . Within 2 week completion chemotherapy , patient undergo surgery . Within 2 week surgery , patient HER-2/neu-positive tumor resume trastuzumab treatment 1 year . After completion study treatment , patient follow periodically least 5 year . PROJECTED ACCRUAL : A total 1,500 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unilateral bilateral primary breast cancer Meets 1 follow stag criterion : Clinical stage T4 T3 disease Clinical stage T1 pathologic stage N+ sentinel lymph node biopsy OR clinical stage T2 , N+ disease AND estrogen receptor ( ER ) progesterone receptor ( PR ) positive tumor ER PR negative tumor ( T14 , N03 , M0 ) Disease confirm core biopsy No fineneedle aspiration incisional biopsy Bidimensionally measurable disease* Tumor lesion palpable measure ≥ 2 cm OR tumor lesion ≥ 1 cm maximum diameter sonography For inflammatory disease , extent inflammation use measurable lesion NOTE : *In patient multifocal multicentric breast cancer , large lesion measure Candidate adjuvant chemotherapy No low moderaterisk patient doubtful candidate adjuvant chemotherapy fulfill stag criterion Known HER2/neu status core biopsy HER2/neu positive tumor define +3 immunohistochemistry [ IHC ] OR positive fluorescence situ hybridization ( FISH ) No evidence distant metastasis Hormone receptor status : ER PRpositive tumor OR ER PRnegative tumor PATIENT CHARACTERISTICS : No male patient Menopausal status specify Karnofsky performance status 80100 % Life expectancy ≥ 10 year ( disregard diagnosis cancer ) Normal cardiac function confirm ECG LVEF ≥ 55 % cardiac ultrasound Neutrophil count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Bilirubin normal AST ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ( AP ) ≤ 5 time ULN OR AP ≤ 2.5 time ULN AND AST and/or ALT ≤ 1.5 time ULN Creatinine ≤ 2 mg/dL Creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception No motor sensory neuropathy ≥ grade 2 No malignancy within past 5 year except carcinoma situ cervix nonmelanoma skin cancer No New York Heart Association class IIIV congestive heart failure No coronary artery disease No history myocardial infarction No uncontrolled arterial hypertension ( i.e. , blood pressure ≥ 160/90 mm Hg despite antihypertensive therapy ) No rhythm abnormalities require permanent therapy No history significant neurological psychiatric disorder include psychotic disorder , dementia , seizure would preclude give informed consent No active infection No active peptic ulcer No unstable diabetes mellitus insulindependent type II diabetes mellitus No serious illness medical condition No know hypersensitivity reaction investigational compound incorporate substances No definite contraindication use corticosteroids No known dihydropyrimidine dehydrogenase deficiency Must fit anthracycline/taxanecontaining chemotherapy PRIOR CONCURRENT THERAPY : No prior chemotherapy malignancy No prior radiation therapy breast cancer No concurrent bisphosphonates chemotherapy Bisphosphonates allow postoperatively No chronic treatment corticosteroid unless initiate &gt; 6 month prior study entry give low dos ( ≤ 20 mg methylprednisolone equivalent ) No concurrent amifostine chemotherapy No concurrent cardioprotectors ( e.g. , dexrazoxane ) chemotherapy No concurrent sex hormone therapy No concurrent virostatic agent ( e.g. , sorivudine brivudine ) No concurrent aminoglycosides No concurrent experimental drug anticancer therapy At least 30 day since prior participation another clinical trial investigational ( market ) drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
</DOC>